These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33318935)

  • 1. Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management.
    Yanase T; Moritoki Y; Kondo H; Ueyama D; Akita H; Yasui T
    Urol Case Rep; 2021 Jan; 34():101508. PubMed ID: 33318935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report.
    Takada R; Fujiwara M; Maki M; Nomura N; Kono S; Fujita A; Masumoto H; Takahashi Y; Hasegawa Y; Tamura K
    J Pharm Health Care Sci; 2024 May; 10(1):26. PubMed ID: 38822426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis.
    Xing P; Zhang F; Wang G; Xu Y; Li C; Wang S; Guo Y; Cai S; Wang Y; Li J
    J Immunother Cancer; 2019 Dec; 7(1):341. PubMed ID: 31801636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
    Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
    J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
    Chapman PB; Jayaprakasam VS; Panageas KS; Callahan M; Postow MA; Shoushtari AN; Wolchok JD; Betof Warner A
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34702752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Case of Metastatic Fumarate Hydratase-Deficient-like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab.
    Sekito T; Takamoto A; Kobayashi Y; Mitsui M; Watari S; Kubota R; Sadahira T; Iwata T; Nishimura S; Edamura K; Sako T; Araki M; Watanabe M; Watanabe T; Shibata R; Ennishi D; Nasu Y
    Acta Med Okayama; 2021 Jun; 75(3):397-402. PubMed ID: 34176946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
    Jespersen MS; Fanø S; Stenør C; Møller AK
    Eur Heart J Case Rep; 2021 Nov; 5(11):ytab342. PubMed ID: 34870082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
    Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
    Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis.
    Verma N; Jaffer M; Pina Y; Peguero E; Mokhtari S
    Cureus; 2021 Jul; 13(7):e16337. PubMed ID: 34395120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report.
    Chen YH; Liu FC; Hsu CH; Chian CF
    Medicine (Baltimore); 2017 Jul; 96(27):e7350. PubMed ID: 28682883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rare case of nivolumab-related myasthenia gravis and myocarditis in a patient with metastatic gastric cancer.
    Komatsu M; Hirai M; Kobayashi K; Hashidate H; Fukumoto J; Sato A; Usuda H; Tanaka K; Takahashi K; Kuwabara S
    BMC Gastroenterol; 2021 Aug; 21(1):333. PubMed ID: 34445963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
    Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
    Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Site-specific patterns of early response to nivolumab plus ipilimumab therapy in advanced renal cell carcinoma patients compared with tyrosine-kinase inhibitors.
    Kato R; Matsuura T; Maekawa S; Kato Y; Kanehira M; Takata R; Obara W
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109443. PubMed ID: 36403521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case report of nivolumab-induced myasthenia gravis and myositis in a metastatic renal cell carcinoma patient.
    Nakanishi S; Nishida S; Miyazato M; Goya M; Saito S
    Urol Case Rep; 2020 Mar; 29():101105. PubMed ID: 31908963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma.
    Fazel M; Jedlowski PM
    Case Reports Immunol; 2019; 2019():2539493. PubMed ID: 31183226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab-Induced Myasthenia Gravis With Myocarditis in the Setting of Metastatic Renal Cell Carcinoma.
    Taboada P; Lee M; Hoyer R; Gray Z; Wang J
    Cureus; 2024 Aug; 16(8):e68318. PubMed ID: 39350808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report.
    Motonaga A; Nakanishi S; Tanaka K; Nishida S; Izumi K; Saito S
    Urol Case Rep; 2021 Sep; 38():101661. PubMed ID: 33868946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit.
    Deharo F; Carvelli J; Cautela J; Garcia M; Sarles C; Maues de Paula A; Bourenne J; Gainnier M; Bichon A
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
    Callahan MK; Kluger H; Postow MA; Segal NH; Lesokhin A; Atkins MB; Kirkwood JM; Krishnan S; Bhore R; Horak C; Wolchok JD; Sznol M
    J Clin Oncol; 2018 Feb; 36(4):391-398. PubMed ID: 29040030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitor-induced myasthenia gravis, myocarditis, and myositis: A case report.
    Basnet A; Sharma NR; Gautam S; Lamichhane S; Kansakar S; Tiwari K; Pokhrel M; Singh S
    Clin Case Rep; 2024 Jun; 12(6):e8968. PubMed ID: 38863868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.